CCCC CIK: 1662579

C4 Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
326
FY22:
288
FY23:
271
FY24:
258
FY25:
258
(positive)
Change from FY21 to FY25
millions USD
FY21:
181
FY22:
143
FY23:
105
FY24:
91.8
FY25:
101
Total assets
Change from FY21 to FY25
millions USD
FY21:
507
FY22:
431
FY23:
376
FY24:
350
FY25:
359

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
51.2
FY22:
44.5
FY23:
42.8
FY24:
45.2
FY25:
33.0
(negative)
Change from FY21 to FY25
millions USD
FY21:
65.9
FY22:
97.1
FY23:
87.6
FY24:
88.4
FY25:
69.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
390
FY22:
289
FY23:
246
FY24:
216
FY25:
257
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
507
FY22:
431
FY23:
376
FY24:
350
FY25:
359

All amounts in millions USD Data source:SEC EDGAR